Endocyte, Inc. (Nasdaq:ECYT), announced financial results for the third quarter ending Sept. 30, 2014, and provided a business and clinical update. Endocyte reported a net loss of $5.7 million, or $0.14 per basic and diluted share, for the third quarter of 2014, compared to a net loss of $3.0 million, or $0.08 per basic and diluted share, for the same period in 2013. Endocyte, Inc. (NASDAQ:ECYT) belongs to Healthcare sector. Its net profit margin is 13.40% and weekly performance is -7.72%. On last trading day company shares ended up $5.50. Endocyte, Inc. (NASDAQ:ECYT) distance from 50-day simple moving average (SMA50) is -16.36%. Cempra Inc (NASDAQ:CEMP), a drug developer without a product in the market currently, fared well in the latest quarter – 3Q. The company achieved two remarkable endpoints in the latest quarter. Its loss narrowed and revenue edged up in the quarter. Both columns drew support from milestone payments under a collaborative drug development agreement with a Japanese company. Cempra Inc (NASDAQ:CEMP) reported a smaller loss of just about $11.4 million. That compared with a loss of $13.6 million in the same quarter last year. Cempra, Inc. (NASDAQ:CEMP) shares fell -0.21% in last trading session and ended the day at $13.99. CEMP Gross Margin is value missing and its return on assets is -72.60%. Cempra, Inc. (NASDAQ:CEMP) quarterly performance is 51.90%. Insulet Corporation (NASDAQ:PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced the promotion of Allison Dorval to Chief Financial Officer effective November 6, 2014 and Brad Thomas as Executive Vice President, Human Resources and Organizational Development, effective immediately. On 05 November, Insulet Corporation (NASDAQ:PODD) shares fell -1.01% and was closed at $40.27. PODD EPS growth in last 5 year was 24.70%. Insulet Corporation (NASDAQ:PODD) year to date (YTD) performance is 8.54%. Convergys Corp. (NYSE:CVG) reported Q3 EPS of $0.42, $0.04 better than the analyst estimate of $0.38. Revenue for the quarter came in at $750 million versus the consensus estimate of $751.5 million. Convergys Corporation (NYSE:CVG) ended the last trading day at $20.11. Company weekly volatility is calculated as 2.10% and price to cash ratio as 10.34. Convergys Corporation (NYSE:CVG) showed a weekly performance of 2.86%. USG Corporation (NYSE:USG) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on October 29. They currently have a $25.30 target price on the stock. Zacks‘s target price indicates a potential downside of 5.24% from the company’s current price. USG Corporation (NYSE:USG) shares increased 0.38% in last trading session and ended the day at $26.52. USG Gross Margin is 17.50% and its return on assets is 2.10%. USG Corporation (NYSE:USG) quarterly performance is -0.75%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
